Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTim R. Cresseyen_US
dc.contributor.authorRohan Hazraen_US
dc.contributor.authorAndrew Wizniaen_US
dc.contributor.authorMarc Focaen_US
dc.contributor.authorPatrick Jean-Philippeen_US
dc.contributor.authorBobbie Grahamen_US
dc.contributor.authorJennifer R. Kingen_US
dc.contributor.authorPaula Brittoen_US
dc.contributor.authorVincent J. Careyen_US
dc.contributor.authorEdward P. Acostaen_US
dc.contributor.authorRam Yogeven_US
dc.description.abstract© 2016 Wolters Kluwer Health, Inc. All rights reserved. HIV protease inhibitor use in pediatrics is challenging due to the poor palatability and/or toxicity of concomitant low-dose ritonavir. Atazanavir without ritonavir (unboosted) is not recommended for patients with prior virologic failure, a common problem for perinatally-infected adolescents. Atazanavir 400 mg once-daily provided suboptimal exposure. Higher unboosted doses or splitting the daily dose to twice-daily warrants investigation in this treatment-experienced population.en_US
dc.titlePharmacokinetics of unboosted atazanavir in treatment-experienced HIV-infected children, adolescents and young adultsen_US
article.title.sourcetitlePediatric Infectious Disease Journalen_US
article.volume35en_US Mai Universityen_US School of Public Healthen_US Institute of Child Health and Human Developmenten_US Medical Centeren_US University Medical Centeren_US Institute of Allergy and Infectious Diseasesen_US Science and Technologyen_US of Alabama at Birminghamen_US University Feinberg School of Medicineen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.

Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.